| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease SR Targan, SB Hanauer, SJH Van Deventer, L Mayer, DH Present, ... New England Journal of Medicine 337 (15), 1029-1036, 1997 | 4126 | 1997 |
| Infliximab for the treatment of fistulas in patients with Crohn's disease DH Present, P Rutgeerts, S Targan, SB Hanauer, L Mayer, ... New England Journal of Medicine 340 (18), 1398-1405, 1999 | 3498 | 1999 |
| Infliximab maintenance therapy for fistulizing Crohn's disease BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, ... New England Journal of Medicine 350 (9), 876-885, 2004 | 2818 | 2004 |
| Polyp miss rate determined by tandem colonoscopy: a systematic review JC Van Rijn, JB Reitsma, J Stoker, PM Bossuyt, SJ Van Deventer, ... Official journal of the American College of Gastroenterology| ACG 101 (2 …, 2006 | 1627 | 2006 |
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial G D'Haens, F Baert, G van Assche, P Caenepeel, P Vergauwe, ... The Lancet 371 (9613), 660-667, 2008 | 1472 | 2008 |
| Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) HM Van Dullemen, SJH van Deventer, DW Hommes, HA Bijl, J Jansen, ... Gastroenterology 109 (1), 129-135, 1995 | 1436 | 1995 |
| Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations J Hampe, A Cuthbert, PJP Croucher, MM Mirza, S Mascheretti, S Fisher, ... The Lancet 357 (9272), 1925-1928, 2001 | 1426 | 2001 |
| Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease P Rutgeerts, G D'Haens, S Targan, E Vasiliauskas, SB Hanauer, ... Gastroenterology 117 (4), 761-769, 1999 | 1337 | 1999 |
| Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways SJ Van Deventer, HR Buller, JW ten Cate, LA Aarden, CE Hack, A Sturk | 1185 | 1990 |
| Natalizumab induction and maintenance therapy for Crohn's disease WJ Sandborn, JF Colombel, R Enns, BG Feagan, SB Hanauer, ... New England Journal of Medicine 353 (18), 1912-1925, 2005 | 1082 | 2005 |
| Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial G D'Haens, S Van Deventer, R Van Hogezand, D Chalmers, C Kothe, ... Gastroenterology 116 (5), 1029-1034, 1999 | 948 | 1999 |
| A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease H Braat, P Rottiers, DW Hommes, N Huyghebaert, E Remaut, JP Remon, ... Clinical gastroenterology and hepatology 4 (6), 754-759, 2006 | 947 | 2006 |
| Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease JMH Van den Brande, H Braat, GR Van Den Brink, HH Versteeg, ... Gastroenterology 124 (7), 1774-1785, 2003 | 913 | 2003 |
| Activation of coagulation after administration of tumor necrosis factor to normal subjects T Van Der Poll, HR Büller, H Ten Cate, CH Wortel, KA Bauer, ... New England Journal of Medicine 322 (23), 1622-1627, 1990 | 848 | 1990 |
| Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease T Ten Hove, C Van Montfrans, MP Peppelenbosch, SJH Van Deventer Gut 50 (2), 206-211, 2002 | 734 | 2002 |
| Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease RN Fedorak, A Gangl, CO Elson, P Rutgeerts, S Schreiber, G Wild, ... Gastroenterology 119 (6), 1473-1482, 2000 | 698 | 2000 |
| Mucosal tumor necrosis factor-or, interleukin-1/3, and interleukin-8 production in patients with helicobacter pylori infection LA Noach, NB Bosma, J Jansen, FJ Hoek, SJH Van Deventer, GNJ Tytgat Scandinavian journal of gastroenterology 29 (5), 425-429, 1994 | 671 | 1994 |
| Tumour necrosis factor and Crohn's disease. SJ Van Deventer Gut 40 (4), 443, 1997 | 666 | 1997 |
| Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease S Schreiber, RN Fedorak, OH Nielsen, G Wild, CN Williams, S Nikolaus, ... Gastroenterology 119 (6), 1461-1472, 2000 | 646 | 2000 |
| Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets DW Hommes, MP Peppelenbosch, SJH Van Deventer Gut 52 (1), 144-151, 2003 | 628 | 2003 |
Cornelis Erik HackHoogleraar Immunologie, Universitair Medisch Centrum UtrechtAdresse e-mail validée de Umcutrecht.nl